{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:05:23Z","timestamp":1790798723398,"version":"4.1.0"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973251"],"award-info":[{"award-number":["81973251"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hebei Province Funding Project for Introduced Overseas Personnel","award":["C20230351"],"award-info":[{"award-number":["C20230351"]}]},{"name":"Hebei Provincial Health Commission Government-Funded Clinical Medicine Talent Program","award":["ZF2024048"],"award-info":[{"award-number":["ZF2024048"]}]},{"name":"Shijiazhuang Basic Research Project","award":["241791397A"],"award-info":[{"award-number":["241791397A"]}]},{"name":"Hebei Province Key Science and Technology Support Program","award":["25242701D"],"award-info":[{"award-number":["25242701D"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07966-w","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T08:15:20Z","timestamp":1772439320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies"],"prefix":"10.1186","volume":"24","author":[{"given":"Mingxin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoxing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4932-3561","authenticated-orcid":false,"given":"Zhiyun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"8","key":"7966_CR1","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.drudis.2021.05.009","volume":"26","author":"XY Ma","year":"2021","unstructured":"Ma XY, Wei L, Lei Z, Chen Y, Ding Z, Chen ZS. Recent progress on targeting leukemia stem cells. Drug Discov Today. 2021;26(8):1904\u201313.","journal-title":"Drug Discov Today"},{"issue":"8","key":"7966_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1208\/s12249-023-02670-0","volume":"24","author":"U Hani","year":"2023","unstructured":"Hani U, Gowda B, Haider N, et al. Nanoparticle-based approaches for treatment of hematological malignancies: acomprehensive review. AAPS PharmSciTech. 2023;24(8):233.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"7966_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/mm9.0000000000000004","volume":"1","author":"S Wang","year":"2024","unstructured":"Wang S, Ma R, Mei Z, Hou Y. Metalloptosis: metal ions-induced programmed cell death based on nanomaterials for cancer therapy. Medmat. 2024;1(1):6\u201326.","journal-title":"Medmat"},{"issue":"6","key":"7966_CR4","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1039\/D1CS00755F","volume":"51","author":"T Ci","year":"2022","unstructured":"Ci T, Zhang W, Qiao Y, et al. Delivery strategies in treatments of leukemia. Chem Soc Rev. 2022;51(6):2121\u201344.","journal-title":"Chem Soc Rev"},{"issue":"21","key":"7966_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41568-021-00355-z","volume":"7","author":"AEPTCG Whiteley","year":"2021","unstructured":"Whiteley AEPTCG. Leukaemia: a model metastatic disease. Nat Rev Cancer. 2021;7(21):461\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7966_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1186\/s40001-023-01539-z","volume":"28","author":"MM Salama","year":"2023","unstructured":"Salama MM, Aborehab NM, El MN, Zayed A, Ezzat SM. Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials. Eur J Med Res. 2023;28(1):566.","journal-title":"Eur J Med Res"},{"key":"7966_CR7","doi-asserted-by":"publisher","first-page":"121771","DOI":"10.1016\/j.lfs.2023.121771","volume":"325","author":"E Pardhi","year":"2023","unstructured":"Pardhi E, Yadav R, Chaurasiya A, et al. Multifunctional targetable liposomal drug delivery system in the management of leukemia: potential, opportunities, and emerging strategies. Life Sci. 2023;325:121771.","journal-title":"Life Sci"},{"issue":"12","key":"7966_CR8","doi-asserted-by":"publisher","first-page":"6478","DOI":"10.1021\/acsbiomaterials.0c01040","volume":"6","author":"J Shen","year":"2020","unstructured":"Shen J, Lu Z, Wang J, et al. Advances of nanoparticles for leukemia treatment. Acs Biomater Sci Eng. 2020;6(12):6478\u201389.","journal-title":"Acs Biomater Sci Eng"},{"key":"7966_CR9","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jconrel.2018.08.034","volume":"287","author":"AK Deshantri","year":"2018","unstructured":"Deshantri AK, Varela MA, Ecker V, et al. Nanomedicines for the treatment of hematological malignancies. J Control Release. 2018;287:194\u2013215.","journal-title":"J Control Release"},{"key":"7966_CR10","doi-asserted-by":"crossref","unstructured":"Wu X, Wang F, Yang X, et al. Advances in drug delivery systems for the treatment of acute myeloid leukemia. Small. 2024:e2403409.","DOI":"10.1002\/smll.202403409"},{"key":"7966_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.drup.2017.05.002","volume":"31","author":"M Bar-Zeev","year":"2017","unstructured":"Bar-Zeev M, Livney YD, Assaraf YG. Targeted nanomedicine for cancer therapeutics: towards precision medicine overcoming drug resistance. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2017;31:15\u201330.","journal-title":"Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother"},{"key":"7966_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jconrel.2019.01.011","volume":"296","author":"S Ghosh","year":"2019","unstructured":"Ghosh S, Lalani R, Patel V, et al. Combinatorial nanocarriers against drug resistance in hematological cancers: opportunities and emerging strategies. J Controlled Release. 2019;296:114\u201339.","journal-title":"J Controlled Release"},{"key":"7966_CR13","doi-asserted-by":"publisher","first-page":"100777","DOI":"10.1016\/j.drup.2021.100777","volume":"58","author":"Z Su","year":"2021","unstructured":"Su Z, Dong S, Zhao S, et al. Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2021;58:100777.","journal-title":"Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother"},{"issue":"1","key":"7966_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","volume":"8","author":"D Fan","year":"2023","unstructured":"Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Signal Transduct Target Ther. 2023;8(1):293.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"7966_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3892\/ol.2024.14389","volume":"27","author":"F Wu","year":"2024","unstructured":"Wu F, Pang H, Li F, Hua M, Song C, Tang J. Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (review). Oncol Lett. 2024;27(6):256.","journal-title":"Oncol Lett"},{"issue":"7","key":"7966_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","volume":"21","author":"M Goebeler","year":"2024","unstructured":"Goebeler M, Stuhler G, Bargou R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat Rev Clin Oncol. 2024;21(7):539\u201360.","journal-title":"Nat Rev Clin Oncol"},{"key":"7966_CR17","doi-asserted-by":"publisher","first-page":"107519","DOI":"10.1016\/j.jddst.2025.107519","volume":"114","author":"AC Ochioni","year":"2025","unstructured":"Ochioni AC, Vieira IRS, Junior CAC. Advances in stimuli-responsive nanoparticles for cancer therapy: mechanisms, functional materials, and emerging technologies. J Drug Deliv Sci Technol. 2025;114:107519.","journal-title":"J Drug Deliv Sci Technol"},{"key":"7966_CR18","doi-asserted-by":"publisher","first-page":"114505","DOI":"10.1016\/j.biopha.2023.114505","volume":"161","author":"J Gong","year":"2023","unstructured":"Gong J, Shi T, Liu J, et al. Dual-drug codelivery nanosystems: an emerging approach for overcoming cancer multidrug resistance. Biomed Pharmacother. 2023;161:114505.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"7966_CR19","doi-asserted-by":"publisher","first-page":"104241","DOI":"10.1016\/j.drudis.2024.104241","volume":"29","author":"M Grairi","year":"2024","unstructured":"Grairi M, Le Borgne M. Antibody-drug conjugates: prospects for the next generation. Drug Discov Today. 2024;29(12):104241.","journal-title":"Drug Discov Today"},{"issue":"13","key":"7966_CR20","doi-asserted-by":"publisher","first-page":"e1902604","DOI":"10.1002\/adma.201902604","volume":"32","author":"P Mi","year":"2020","unstructured":"Mi P, Cabral H, Kataoka K. Ligand-installed nanocarriers toward precision therapy. Adv Mater. 2020;32(13):e1902604.","journal-title":"Adv Mater"},{"issue":"2","key":"7966_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/13543784.2023.2179482","volume":"32","author":"JW Morse","year":"2023","unstructured":"Morse JW, Rios M, Ye J, et al. Antibody therapies for the treatment of Acute myeloid leukemia: exploring current and emerging therapeutic targets. Expert Opin Investig Drugs. 2023;32(2):107\u201325.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"7966_CR22","doi-asserted-by":"publisher","first-page":"5689","DOI":"10.1038\/s41467-024-50021-9","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Wu H, Yu Z, et al. Hematopoietic stem and progenitor cell membrane-coated vesicles for bone marrow-targeted leukaemia drug delivery. Nat Commun. 2024;15(1):5689.","journal-title":"Nat Commun"},{"key":"7966_CR23","doi-asserted-by":"publisher","first-page":"607692","DOI":"10.3389\/fimmu.2021.607692","volume":"12","author":"PV Candelaria","year":"2021","unstructured":"Candelaria PV, Leoh LS, Penichet ML, Daniels-Wells TR. Antibodies targeting the transferrin receptor 1 (TFR1) as direct anti-cancer agents. Front Immunol. 2021;12:607692.","journal-title":"Front Immunol"},{"key":"7966_CR24","doi-asserted-by":"publisher","first-page":"1093750","DOI":"10.3389\/fimmu.2023.1093750","volume":"14","author":"G Wu","year":"2023","unstructured":"Wu G, Guo S, Luo Q, et al. Preclinical evaluation of CD70 - specific car t cells targeting acute myeloid leukemia. Front Immunol. 2023;14:1093750.","journal-title":"Front Immunol"},{"issue":"13","key":"7966_CR25","doi-asserted-by":"publisher","first-page":"e33754","DOI":"10.1016\/j.heliyon.2024.e33754","volume":"10","author":"FM Alkhulaifi","year":"2024","unstructured":"Alkhulaifi FM, Alonaizan R, Rady A, Alomar S. Study of gene polymorphisms in toll-like receptor 2 in patients with acute lymphoblastic leukemia. Heliyon. 2024;10(13):e33754.","journal-title":"Heliyon"},{"issue":"3","key":"7966_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ijc.28382","volume":"134","author":"K Li","year":"2014","unstructured":"Li K, Lv XX, Hua F, et al. Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide. Int J Cancer. 2014;134(3):692\u2013702.","journal-title":"Int J Cancer"},{"issue":"14","key":"7966_CR27","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.3390\/ijms23147542","volume":"23","author":"M Gallazzi","year":"2022","unstructured":"Gallazzi M, Ucciero M, Faraci DG, et al. New frontiers in monoclonal antibodies for the targeted therapy of acute myeloid leukemia and myelodysplastic syndromes. Int J Mol Sci. 2022;23(14):7542.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"7966_CR28","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.3390\/cancers15112944","volume":"15","author":"J Zarychta","year":"2023","unstructured":"Zarychta J, Kowalczyk A, Krawczyk M, Lejman M, Zawitkowska J. Car-t cells immunotherapies for the treatment of Acute myeloid leukemia-recent advances. Cancers (Basel). 2023;15(11):2944.","journal-title":"Cancers (Basel)"},{"key":"7966_CR29","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1182\/blood-2023-187642","volume":"142","author":"D Dutta","year":"2023","unstructured":"Dutta D, Pan P, Fleing R, et al. First disclosure of azd9829, a top1i-adc targeting CD123 : promising preclinical activity in aml models with minimal effect on healthy progenitors. Blood. 2023;142:5957.","journal-title":"Blood"},{"issue":"1","key":"7966_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","volume":"14","author":"Z Jiang","year":"2021","unstructured":"Jiang Z, Sun H, Yu J, Tian W, Song Y. Targeting CD47 for cancer immunotherapy. J Hematol Oncol. 2021;14(1):180.","journal-title":"J Hematol Oncol"},{"key":"7966_CR31","doi-asserted-by":"publisher","first-page":"100928","DOI":"10.1016\/j.blre.2022.100928","volume":"54","author":"C Cumbo","year":"2022","unstructured":"Cumbo C, Tarantini F, Anelli L, et al. Flt3 mutational analysis in acute myeloid leukemia: advantages and pitfalls with different approaches. Blood Rev. 2022;54:100928.","journal-title":"Blood Rev"},{"issue":"10388","key":"7966_CR32","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(23)00617-7","volume":"401","author":"AC Przespolewski","year":"2023","unstructured":"Przespolewski AC, Griffiths EA. FLT3-mutated Acute myeloid leukaemia: a new opportunity. Lancet. 2023;401(10388):1546\u20138.","journal-title":"Lancet"},{"issue":"1","key":"7966_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1200\/JCO-25-01841","volume":"44","author":"P Montesinos","year":"2026","unstructured":"Montesinos P, Rodr\u00edguez-Veiga R, Bergua JM, et al. Quizartinib for newly diagnosed FLT3-internal tandem duplication-negative aml: the randomized, double-blind, placebo-controlled, phase ii quiwi study. J Clin Oncology: Official J Am Soc Clin Oncol. 2026;44(1):42\u201353.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"10","key":"7966_CR34","doi-asserted-by":"publisher","first-page":"7945","DOI":"10.1007\/s00432-022-04444-w","volume":"149","author":"S Bao","year":"2023","unstructured":"Bao S, Darvishi M. Cxc chemokine receptor 4 (CXCR4) blockade in cancer treatment. J Cancer Res Clin Oncol. 2023;149(10):7945\u201368.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"7966_CR35","doi-asserted-by":"publisher","first-page":"e13076","DOI":"10.1111\/cpr.13076","volume":"54","author":"L Su","year":"2021","unstructured":"Su L, Hu Z, Yang YG. Role of cxcr4 in the progression and therapy of acute leukaemia. Cell Prolif. 2021;54(7):e13076.","journal-title":"Cell Prolif"},{"key":"7966_CR36","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.1182\/blood-2023-188251","volume":"142","author":"B Francica","year":"2023","unstructured":"Francica B, Garner E, Namburi S, et al. Cll-1-targeted allogeneic car-t cells exhibit high on- target specificity and potent cytotoxicity in preclinical models of Acute myeloid leukemia. Blood. 2023;142:6838.","journal-title":"Blood"},{"issue":"21","key":"7966_CR37","doi-asserted-by":"publisher","first-page":"eabg3217","DOI":"10.1126\/sciadv.abg3217","volume":"7","author":"T Ho","year":"2021","unstructured":"Ho T, Kim HS, Chen Y, et al. Scaffold-mediated crispr-cas9 delivery system for acute myeloid leukemia therapy. Sci Adv. 2021;7(21):eabg3217.","journal-title":"Sci Adv"},{"key":"7966_CR38","doi-asserted-by":"publisher","first-page":"114113","DOI":"10.1016\/j.addr.2022.114113","volume":"182","author":"G Kara","year":"2022","unstructured":"Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022;182:114113.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"7966_CR39","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41375-023-01854-8","volume":"37","author":"H Issa","year":"2023","unstructured":"Issa H, Swart LEE, Rasouli M, et al. Nanoparticle-mediated targeting of the fusion gene runx1 \/ eto in t (8;21)- positive Acute myeloid leukaemia. Leukemia. 2023;37(4):820\u201334.","journal-title":"Leukemia"},{"key":"7966_CR40","doi-asserted-by":"publisher","first-page":"112663","DOI":"10.1016\/j.msec.2022.112663","volume":"134","author":"SA Mohammed","year":"2022","unstructured":"Mohammed SA, Ju Y. Multifunctional liposomal nanostructure-mediated sirna\/bortezomib co-delivery for sharp1 knockdown in mll-af6 acute myeloid leukemia. Biomater Adv. 2022;134:112663.","journal-title":"Biomater Adv"},{"issue":"1","key":"7966_CR41","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc Chem Res. 2022;55(1):2\u201312.","journal-title":"Acc Chem Res"},{"key":"7966_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jconrel.2020.03.020","volume":"322","author":"C Peng","year":"2020","unstructured":"Peng C, Huang Y, Zheng J. Renal clearable nanocarriers: overcoming the physiological barriers for precise drug delivery and clearance. J Controlled Release: Official J Controlled Release Soc. 2020;322:64\u201380.","journal-title":"J Controlled Release: Official J Controlled Release Soc"},{"issue":"2","key":"7966_CR43","doi-asserted-by":"publisher","first-page":"e1856","DOI":"10.1002\/wnan.1856","volume":"15","author":"MA Sufian","year":"2023","unstructured":"Sufian MA, Ilies MA. Lipid-based nucleic acid therapeutics with in vivo efficacy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023;15(2):e1856.","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"21","key":"7966_CR44","doi-asserted-by":"publisher","first-page":"20825","DOI":"10.1021\/acsnano.3c05853","volume":"17","author":"M Xu","year":"2023","unstructured":"Xu M, Qi Y, Liu G, Song Y, Jiang X, Du B. Size-dependent in vivo transport of nanoparticles: implications for delivery, targeting, and clearance. ACS Nano. 2023;17(21):20825\u201349.","journal-title":"ACS Nano"},{"issue":"4","key":"7966_CR45","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/molecules27041310","volume":"27","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Lin W, Zhu L. Targeted drug delivery for the treatment of blood cancers. Molecules. 2022;27(4):1310.","journal-title":"Molecules"},{"issue":"3","key":"7966_CR46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.0721","volume":"28","author":"JA Kulkarni","year":"2018","unstructured":"Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28(3):146\u201357.","journal-title":"Nucleic Acid Ther"},{"key":"7966_CR47","doi-asserted-by":"publisher","first-page":"115448","DOI":"10.1016\/j.addr.2024.115448","volume":"214","author":"E Garbayo","year":"2024","unstructured":"Garbayo E, El Moukhtari SH, Rodr\u00edguez-Nogales C, et al. Rna-loaded nanoparticles for the treatment of hematological cancers. Adv Drug Deliv Rev. 2024;214:115448.","journal-title":"Adv Drug Deliv Rev"},{"key":"7966_CR48","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","volume":"361","author":"SH El Moukhtari","year":"2023","unstructured":"El Moukhtari SH, Garbayo E, Amundarain A, et al. Lipid nanoparticles for sirna delivery in cancer treatment. J Controlled Release: Official J Controlled Release Soc. 2023;361:130\u201346.","journal-title":"J Controlled Release: Official J Controlled Release Soc"},{"issue":"6","key":"7966_CR49","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","volume":"11","author":"GC Issa","year":"2021","unstructured":"Issa GC, DiNardo CD. Acute myeloid leukemia with idh1 and idh2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021;11(6):107.","journal-title":"Blood Cancer J"},{"issue":"4","key":"7966_CR50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/14728222.2021.1915991","volume":"25","author":"F Gonzales","year":"2021","unstructured":"Gonzales F, Barthelemy A, Peyrouze P, et al. Targeting runx1 in acute myeloid leukemia: preclinical innovations and therapeutic implications. Expert Opin Ther Targets. 2021;25(4):299\u2013309.","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"7966_CR51","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41375-023-02117-2","volume":"38","author":"H Akiyama","year":"2024","unstructured":"Akiyama H, Zhao R, Ostermann LB, et al. Mitochondrial regulation of gpx4 inhibition-mediated ferroptosis in Acute myeloid leukemia. Leukemia. 2024;38(4):729\u201340.","journal-title":"Leukemia"},{"key":"7966_CR52","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.blre.2024.101195","volume":"65","author":"DJ Fowler-Shorten","year":"2024","unstructured":"Fowler-Shorten DJ, Hellmich C, Markham M, Bowles KM, Rushworth SA. Bcl-2 inhibition in haematological malignancies: clinical application and complications. Blood Rev. 2024;65:101195.","journal-title":"Blood Rev"},{"key":"7966_CR53","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.mito.2019.04.010","volume":"47","author":"W Xie","year":"2019","unstructured":"Xie W, Ma W, Liu P, Zhou F. Overview of thioredoxin system and targeted therapies for acute leukemia. Mitochondrion. 2019;47:38\u201346.","journal-title":"Mitochondrion"},{"issue":"3","key":"7966_CR54","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","volume":"20","author":"D Vetrie","year":"2020","unstructured":"Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer. 2020;20(3):158\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"7966_CR55","doi-asserted-by":"publisher","first-page":"e914","DOI":"10.1097\/HS9.0000000000000914","volume":"7","author":"S Turkalj","year":"2023","unstructured":"Turkalj S, Radtke FA, Vyas P. An overview of targeted therapies in acute myeloid leukemia. Hemasphere. 2023;7(6):e914.","journal-title":"Hemasphere"},{"issue":"8015","key":"7966_CR56","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41586-024-07410-3","volume":"630","author":"Q Luo","year":"2024","unstructured":"Luo Q, Raulston EG, Prado MA, et al. Targetable leukaemia dependency on noncanonical PI3K\u03b3 signalling. Nat (London). 2024;630(8015):198\u2013205.","journal-title":"Nat (London)"},{"issue":"4","key":"7966_CR57","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s43018-024-00736-x","volume":"5","author":"H Dong","year":"2024","unstructured":"Dong H, He X, Zhang L, et al. Targeting prmt9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cgas-mediated anticancer immunity. Nat Cancer. 2024;5(4):601\u201324.","journal-title":"Nat Cancer"},{"issue":"1","key":"7966_CR58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12967-022-03868-9","volume":"21","author":"FM Zhong","year":"2023","unstructured":"Zhong FM, Yao FY, Liu J, et al. Splicing factor-mediated regulation patterns reveals biological characteristics and aid in predicting prognosis in Acute myeloid leukemia. J Transl Med. 2023;21(1):6.","journal-title":"J Transl Med"},{"issue":"2","key":"7966_CR59","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.gendis.2023.03.016","volume":"11","author":"F Yao","year":"2024","unstructured":"Yao F, Zhong F, Jiang J, et al. The m6a regulator kiaa1429 stabilizes rab27b mrna and promotes the progression of Chronic myeloid leukemia and resistance to targeted therapy. Genes Dis. 2024;11(2):993\u20131008.","journal-title":"Genes Dis"},{"issue":"4","key":"7966_CR60","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.cmet.2024.01.013","volume":"36","author":"M Lu","year":"2024","unstructured":"Lu M, Busquets J, Impedovo V, et al. Slc25a51 decouples the mitochondrial nad+\/nadh ratio to control proliferation of aml cells. Cell Metab. 2024;36(4):808\u201321.","journal-title":"Cell Metab"},{"issue":"6","key":"7966_CR61","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s43018-024-00761-w","volume":"5","author":"H Lawson","year":"2024","unstructured":"Lawson H, Holt-Martyn JP, Dembitz V, et al. The selective prolyl hydroxylase inhibitor iox5 stabilizes hif-1alpha and compromises development and progression of Acute myeloid leukemia. Nat Cancer. 2024;5(6):916\u201337.","journal-title":"Nat Cancer"},{"issue":"6","key":"7966_CR62","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41556-024-01420-z","volume":"26","author":"L Yang","year":"2024","unstructured":"Yang L, Zhang Z, Jiang P, et al. Phase separation-competent fbl promotes early pre-rrna processing and translation in Acute myeloid leukaemia. Nat Cell Biol. 2024;26(6):946\u201361.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"7966_CR63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.stem.2025.01.013","volume":"32","author":"Z Song","year":"2025","unstructured":"Song Z, Cui Y, Xin L, et al. Mechano-oncogenic cytoskeletal remodeling drives leukemic transformation with mitochondrial vesicle - mediated sting activation. Cell Stem Cell. 2025;32(4):581\u201397.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"7966_CR64","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, et al. Acute myeloid leukemia management and research in 2025. Cancer J Clin. 2025;75(1):46\u201367.","journal-title":"Cancer J Clin"},{"issue":"2","key":"7966_CR65","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.beha.2019.05.005","volume":"32","author":"JE Maakaron","year":"2019","unstructured":"Maakaron JE, Mims AS. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: a new twist on an old cocktail. Best Pract Res Clin Haematol. 2019;32(2):127\u201333.","journal-title":"Best Pract Res Clin Haematol"},{"key":"7966_CR66","doi-asserted-by":"crossref","unstructured":"Laszig S, Diederichs A, Salzmann-Manrique E, et al. Cpx-351 in down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3\u00a0ml-ds 2018 trial. Blood. 2025:2025030775.","DOI":"10.1182\/blood.2025030775"},{"issue":"5","key":"7966_CR67","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100(5):860\u201391.","journal-title":"Am J Hematol"},{"key":"7966_CR68","doi-asserted-by":"publisher","first-page":"101286","DOI":"10.1016\/j.drup.2025.101286","volume":"83","author":"F Song","year":"2025","unstructured":"Song F, Lin S, Xu T, et al. Targeted therapy in acute myeloid leukemia: resistance and overcoming strategy. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2025;83:101286.","journal-title":"Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother"},{"issue":"5","key":"7966_CR69","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","volume":"45","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Konopleva M. Aml treatment: conventional chemotherapy and emerging novel agents. Trends Pharmacol Sci. 2024;45(5):430\u201348.","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"7966_CR70","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22(8):641\u201361.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"7966_CR71","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang R, Hu B, Pan Z, et al. Antibody-drug conjugates (ADCS): current and future biopharmaceuticals. J Hematol Oncol. 2025;18(1):51.","journal-title":"J Hematol Oncol"},{"key":"7966_CR72","doi-asserted-by":"publisher","first-page":"115161","DOI":"10.1016\/j.colsurfb.2025.115161","volume":"257","author":"X Yao","year":"2026","unstructured":"Yao X, Lu Y, Shi S, Wang Y. Antibody-drug conjugates (ADCS): smart missiles targeting cancer therapy. Colloids Surf B Biointerfaces. 2026;257:115161.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"7966_CR73","doi-asserted-by":"publisher","first-page":"122676","DOI":"10.1016\/j.lfs.2024.122676","volume":"347","author":"ZX Phuna","year":"2024","unstructured":"Phuna ZX, Kumar PA, Haroun E, Dutta D, Lim SH. Antibody-drug conjugates: principles and opportunities. Life Sci. 2024;347:122676.","journal-title":"Life Sci"},{"issue":"2","key":"7966_CR74","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1021\/acs.biomac.2c01269","volume":"24","author":"U Huynh","year":"2023","unstructured":"Huynh U, Wu P, Qiu J, et al. Targeted drug delivery using a plug-to-direct antibody-nanogel-conjugate (ANC). Biomacromolecules. 2023;24(2):849\u201357.","journal-title":"Biomacromolecules"},{"issue":"2","key":"7966_CR75","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/17425247.2016.1213238","volume":"14","author":"EN Abd","year":"2017","unstructured":"Abd EN, Abouelmagd SA. Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges. Expert Opin Drug Deliv. 2017;14(2):201\u201314.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"7966_CR76","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13045-022-01390-5","volume":"15","author":"N Baumer","year":"2022","unstructured":"Baumer N, Scheller A, Wittmann L, et al. Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of Acute Myeloid Leukemia. J Hematol Oncol. 2022;15(1):171.","journal-title":"J Hematol Oncol"},{"key":"7966_CR77","doi-asserted-by":"publisher","first-page":"103035","DOI":"10.1016\/j.cis.2023.103035","volume":"322","author":"SV Kaymaz","year":"2023","unstructured":"Kaymaz SV, Nobar HM, Sarigul H, Soylukan C, Akyuz L, Yuce M. Nanomaterial surface modification toolkit: principles, components, recipes, and applications. Adv Colloid Interface Sci. 2023;322:103035.","journal-title":"Adv Colloid Interface Sci"},{"key":"7966_CR78","first-page":"499","volume":"21","author":"Y Xia","year":"2023","unstructured":"Xia Y, An J, Li J, et al. Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical plk1 inhibitor to Acute Myeloid Leukemia. Bioact Mater. 2023;21:499\u2013510.","journal-title":"Bioact Mater"},{"key":"7966_CR79","doi-asserted-by":"publisher","first-page":"115448","DOI":"10.1016\/j.addr.2024.115448","volume":"214","author":"E Garbayo","year":"2024","unstructured":"Garbayo E, El MS, Rodriguez-Nogales C, et al. Rna-loaded nanoparticles for the treatment of hematological cancers. Adv Drug Deliv Rev. 2024;214:115448.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"7966_CR80","doi-asserted-by":"publisher","first-page":"e13255","DOI":"10.1111\/cpr.13255","volume":"55","author":"H Chen","year":"2022","unstructured":"Chen H, Jayasinghe MK, Yeo E, et al. CD33-targeting extracellular vesicles deliver antisense oligonucleotides against FLT3-ITD and MIR-125B for specific treatment of acute myeloid leukaemia. Cell Prolif. 2022;55(9):e13255.","journal-title":"Cell Prolif"},{"issue":"9","key":"7966_CR81","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","volume":"20","author":"MZ Chen","year":"2025","unstructured":"Chen MZ, Yuen D, McLeod VM, et al. A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles. Nat Nanotechnol. 2025;20(9):1273\u201384.","journal-title":"Nat Nanotechnol"},{"issue":"9","key":"7966_CR82","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1039\/D0BM00129E","volume":"8","author":"L Huang","year":"2020","unstructured":"Huang L, Huang J, Huang J, et al. Nanomedicine - a promising therapy for hematological malignancies. Biomater Sci. 2020;8(9):2376\u201393.","journal-title":"Biomater Sci"},{"key":"7966_CR83","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jconrel.2018.07.024","volume":"286","author":"J Guo","year":"2018","unstructured":"Guo J, Luan X, Cong Z, et al. The potential for clinical translation of antibody-targeted nanoparticles in the treatment of Acute Myeloid Leukaemia. J Control Release. 2018;286:154\u201366.","journal-title":"J Control Release"},{"issue":"2","key":"7966_CR84","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/nano10020276","volume":"10","author":"M Houshmand","year":"2020","unstructured":"Houshmand M, Garello F, Circosta P, et al. Nanocarriers as magic bullets in the treatment of leukemia. Nanomaterials (Basel). 2020;10(2):276.","journal-title":"Nanomaterials (Basel)"},{"key":"7966_CR85","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jconrel.2022.03.043","volume":"345","author":"M Ikeda-Imafuku","year":"2022","unstructured":"Ikeda-Imafuku M, Wang LL, Rodrigues D, Shaha S, Zhao Z, Mitragotri S. Strategies to improve the epr effect: a mechanistic perspective and clinical translation. J Control Release. 2022;345:512\u201336.","journal-title":"J Control Release"},{"key":"7966_CR86","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fbioe.2017.00079","volume":"5","author":"R Vinhas","year":"2017","unstructured":"Vinhas R, Mendes R, Fernandes AR, Baptista PV. Nanoparticles-emerging potential for managing leukemia and lymphoma. Front Bioeng Biotechnol. 2017;5:79.","journal-title":"Front Bioeng Biotechnol"},{"issue":"1","key":"7966_CR87","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","volume":"29","author":"R Bajracharya","year":"2022","unstructured":"Bajracharya R, Song JG, Patil BR, et al. Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Deliv. 2022;29(1):1959\u201370.","journal-title":"Drug Deliv"},{"issue":"5","key":"7966_CR88","doi-asserted-by":"publisher","first-page":"55009","DOI":"10.1088\/1748-605X\/ac15b1","volume":"16","author":"P \u0160tef\u00edk","year":"2021","unstructured":"\u0160tef\u00edk P, Annu\u0161ov\u00e1 A, Lakato\u0161 B, et al. Targeting acute myeloid leukemia cells by CD33 receptor-specific mos2-based nanoconjugates. Biomedical Mater (Bristol). 2021;16(5):55009.","journal-title":"Biomedical Mater (Bristol)"},{"issue":"6","key":"7966_CR89","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1021\/mp5008212","volume":"12","author":"H Li","year":"2015","unstructured":"Li H, Xu S, Quan J, et al. CD33-targeted lipid nanoparticles (aCD33LNs) for therapeutic delivery of gti-2040 to Acute Myelogenous Leukemia. Mol Pharm. 2015;12(6):2010\u20138.","journal-title":"Mol Pharm"},{"issue":"10","key":"7966_CR90","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1007\/s13346-020-00893-3","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Cai R, Li H, et al. Construction of a target msns drugcarrier loaded with siRNA(GLI1) and siRNA(SMO) aim at hedgehog signal pathway and the pharmacodynamic study of drug-carriers in the treatment of leukemia stem cells. Drug Deliv Transl Res. 2022;12(10):2463\u201373.","journal-title":"Drug Deliv Transl Res"},{"issue":"7","key":"7966_CR91","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1016\/j.xphs.2021.02.025","volume":"110","author":"S Li","year":"2021","unstructured":"Li S, Zhang L, Li M, et al. Anti-CD19 mab modified mesoporous titanium dioxide as exclusively targeting vector for efficient B-lymphoblastic leukemia therapy. J Pharm Sci. 2021;110(7):2733\u201342.","journal-title":"J Pharm Sci"},{"issue":"8","key":"7966_CR92","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.1021\/acsanm.3c00597","volume":"6","author":"X Huang","year":"2023","unstructured":"Huang X, Li Z, Xiao Z, et al. Multifaceted pt nanoclusters for targeting recognition, cellular uptake, and therapy in vivo and in vitro in Chronic Myeloid Leukemia cells. Acs Appl Nano Mater. 2023;6(8):6879\u201390.","journal-title":"Acs Appl Nano Mater"},{"issue":"7","key":"7966_CR93","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1021\/acs.nanolett.3c00304","volume":"23","author":"D Shi","year":"2023","unstructured":"Shi D, Toyonaga S, Anderson DG. In vivo rna delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles. Nano Lett. 2023;23(7):2938\u201344.","journal-title":"Nano Lett"},{"key":"7966_CR94","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"JE Zhou","year":"2022","unstructured":"Zhou JE, Sun L, Jia Y, et al. Lipid nanoparticles produce chimeric antigen receptor t cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307.","journal-title":"J Control Release"},{"issue":"1","key":"7966_CR95","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s41598-017-18932-4","volume":"8","author":"T Mandal","year":"2018","unstructured":"Mandal T, Beck M, Kirsten N, Linden M, Buske C. Targeting murine leukemic stem cells by antibody functionalized mesoporous silica nanoparticles. Sci Rep. 2018;8(1):989.","journal-title":"Sci Rep"},{"key":"7966_CR96","doi-asserted-by":"publisher","first-page":"1287128","DOI":"10.1155\/2016\/1287128","volume":"2016","author":"Y Yuan","year":"2016","unstructured":"Yuan Y, Zhang L, Cao H, Yang Y, Zheng Y, Yang XJ. A polyethylenimine-containing and transferrin-conjugated lipid nanoparticle system for antisense oligonucleotide delivery to aml. Biomed Res Int. 2016;2016:1287128.","journal-title":"Biomed Res Int"},{"key":"7966_CR97","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.biopha.2016.11.121","volume":"86","author":"B Zhu","year":"2017","unstructured":"Zhu B, Zhang H, Yu L. Novel transferrin modified and doxorubicin loaded pluronic 85\/lipid-polymeric nanoparticles for the treatment of leukemia: in vitro and in vivo therapeutic effect evaluation. Biomed Pharmacother. 2017;86:547\u201354.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"7966_CR98","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s11671-018-2688-x","volume":"13","author":"Y Dai","year":"2018","unstructured":"Dai Y, Huang J, Xiang B, Zhu H, He C. Antiproliferative and apoptosis triggering potential of paclitaxel-based targeted-lipid nanoparticles with enhanced cellular internalization by transferrin receptors-a study in leukemia cells. Nanoscale Res Lett. 2018;13(1):271.","journal-title":"Nanoscale Res Lett"},{"issue":"12","key":"7966_CR99","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/s41565-021-00980-7","volume":"16","author":"C Wang","year":"2021","unstructured":"Wang C, Zhang W, He Y, et al. Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects. Nat Nanotechnol. 2021;16(12):1413\u201323.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"7966_CR100","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12951-021-00921-5","volume":"19","author":"F Palombarini","year":"2021","unstructured":"Palombarini F, Masciarelli S, Incocciati A, et al. Self-assembling ferritin-dendrimer nanoparticles for targeted delivery of nucleic acids to myeloid leukemia cells. J Nanobiotechnol. 2021;19(1):172.","journal-title":"J Nanobiotechnol"},{"key":"7966_CR101","doi-asserted-by":"publisher","first-page":"111583","DOI":"10.1016\/j.msec.2020.111583","volume":"119","author":"D Wang","year":"2021","unstructured":"Wang D, Li H, Chen W, et al. Efficient tumor-targeting delivery of sirna via folate-receptor mediated biomimetic albumin nanoparticles enhanced by all-trans retinoic acid. Mater Sci Eng C Mater Biol Appl. 2021;119:111583.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"11","key":"7966_CR102","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/md16110439","volume":"16","author":"X Wei","year":"2018","unstructured":"Wei X, Liao J, Davoudi Z, et al. Folate receptor-targeted and gsh-responsive carboxymethyl chitosan nanoparticles containing covalently entrapped 6-mercaptopurine for enhanced intracellular drug delivery in leukemia. Mar Drugs. 2018;16(11):439.","journal-title":"Mar Drugs"},{"issue":"1","key":"7966_CR103","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.xphs.2022.04.014","volume":"112","author":"Q Liu","year":"2023","unstructured":"Liu Q, Luo L, Gao X, et al. Co-delivery of daunorubicin and homoharringtonine in folic acid modified-liposomes for enhancing therapeutic effect on Acute Myeloid Leukemia. J Pharm Sci. 2023;112(1):123\u201331.","journal-title":"J Pharm Sci"},{"key":"7966_CR104","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jcis.2016.10.041","volume":"487","author":"J Liu","year":"2017","unstructured":"Liu J, Zhao D, He W, Zhang H, Li Z, Luan Y. Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy. J Colloid Interface Sci. 2017;487:239\u201349.","journal-title":"J Colloid Interface Sci"},{"issue":"1\u20132","key":"7966_CR105","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ijpharm.2015.04.072","volume":"489","author":"NM Danesh","year":"2015","unstructured":"Danesh NM, Lavaee P, Ramezani M, Abnous K, Taghdisi SM. Targeted and controlled release delivery of daunorubicin to T-cell Acute Lymphoblastic Leukemia by aptamer-modified gold nanoparticles. Int J Pharm. 2015;489(1\u20132):311\u20137.","journal-title":"Int J Pharm"},{"issue":"6","key":"7966_CR106","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.1021\/acsami.8b22563","volume":"11","author":"S Zong","year":"2019","unstructured":"Zong S, Wang L, Yang Z, Wang H, Wang Z, Cui Y. Black phosphorus-based drug nanocarrier for targeted and synergetic chemophotothermal therapy of Acute Lymphoblastic Leukemia. Acs Appl Mater Interfaces. 2019;11(6):5896\u2013902.","journal-title":"Acs Appl Mater Interfaces"},{"issue":"7","key":"7966_CR107","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1038\/leu.2015.343","volume":"30","author":"H Zong","year":"2016","unstructured":"Zong H, Sen S, Zhang G, et al. In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche. Leukemia. 2016;30(7):1582\u20136.","journal-title":"Leukemia"},{"key":"7966_CR108","doi-asserted-by":"publisher","first-page":"121258","DOI":"10.1016\/j.biomaterials.2021.121258","volume":"280","author":"V Pallar\u00e8s","year":"2022","unstructured":"Pallar\u00e8s V, Unzueta U, Falg\u00e0s A, et al. A multivalent Ara-c-prodrug nanoconjugate achieves selective ablation of leukemic cells in an Acute Myeloid Leukemia mouse model. Biomaterials. 2022;280:121258.","journal-title":"Biomaterials"},{"key":"7966_CR109","doi-asserted-by":"publisher","first-page":"106503","DOI":"10.1016\/j.phrs.2022.106503","volume":"185","author":"M Zhang","year":"2022","unstructured":"Zhang M, Ge Y, Xu S, et al. Nanomicelles co-loading cxcr4 antagonist and doxorubicin combat the refractory acute myeloid leukemia. Pharmacol Res. 2022;185:106503.","journal-title":"Pharmacol Res"},{"key":"7966_CR110","doi-asserted-by":"publisher","first-page":"104601","DOI":"10.1016\/j.bioorg.2020.104601","volume":"107","author":"C Chittasupho","year":"2021","unstructured":"Chittasupho C, Aonsri C, Imaram W. Targeted dendrimers for antagonizing the migration and viability of nalm-6 lymphoblastic leukemia cells. Bioorg Chem. 2021;107:104601.","journal-title":"Bioorg Chem"},{"issue":"23","key":"7966_CR111","doi-asserted-by":"publisher","first-page":"22128","DOI":"10.1021\/acsanm.3c04297","volume":"6","author":"Q Li","year":"2023","unstructured":"Li Q, Wang F, Bai H, Cui Y, Ma M, Zhang Y. Hollow mesoporous prussian blue nanoparticles loaded with daunorubicin for Acute Myeloid Leukemia treatment. Acs Appl Nano Mater. 2023;6(23):22128\u201341.","journal-title":"Acs Appl Nano Mater"},{"key":"7966_CR112","doi-asserted-by":"publisher","first-page":"215608","DOI":"10.1016\/j.canlet.2022.215608","volume":"533","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Guan L, Li W, et al. Dt7 peptide-modified lecithin nanoparticles co-loaded with gamma-secretase inhibitor and dexamethasone efficiently inhibit t-cell Acute Lymphoblastic Leukemia and reduce gastrointestinal toxicity. Cancer Lett. 2022;533:215608.","journal-title":"Cancer Lett"},{"key":"7966_CR113","doi-asserted-by":"publisher","first-page":"102004","DOI":"10.1016\/j.nano.2019.04.007","volume":"20","author":"TY Lin","year":"2019","unstructured":"Lin TY, Zhu Y, Li Y, et al. Daunorubicin-containing cll1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine. 2019;20:102004.","journal-title":"Nanomedicine"},{"issue":"1","key":"7966_CR114","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","volume":"109","author":"DR Goulet","year":"2020","unstructured":"Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. J Pharm Sci. 2020;109(1):74\u2013103.","journal-title":"J Pharm Sci"},{"issue":"15","key":"7966_CR115","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1016\/j.cell.2022.05.029","volume":"185","author":"PJ Carter","year":"2022","unstructured":"Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell. 2022;185(15):2789\u2013805.","journal-title":"Cell"},{"issue":"6656","key":"7966_CR116","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.ade6967","volume":"381","author":"L Breda","year":"2023","unstructured":"Breda L, Papp TE, Triebwasser MP, et al. In vivo hematopoietic stem cell modification by mrna delivery. Science. 2023;381(6656):436\u201343.","journal-title":"Science"},{"key":"7966_CR117","doi-asserted-by":"publisher","first-page":"13267","DOI":"10.2147\/IJN.S476241","volume":"19","author":"S Bozzer","year":"2024","unstructured":"Bozzer S, Grimaldi MC, De Maso L, et al. Stealth-engineered albumin-coated nanoparticles for targeted therapy: effective drug delivery and tumor suppression in xenograft-zebrafish model. Int J Nanomed. 2024;19:13267\u201386.","journal-title":"Int J Nanomed"},{"issue":"48","key":"7966_CR118","doi-asserted-by":"publisher","first-page":"2411439","DOI":"10.1002\/adfm.202411439","volume":"34","author":"H Chen","year":"2024","unstructured":"Chen H, Wang D, Yao Y, et al. Leukemia cell hitchhiking hypoxia responsive nanogel for improved immunotherapy of Acute Myeloid Leukemia. Adv Funct Mater. 2024;34(48):2411439.","journal-title":"Adv Funct Mater"},{"issue":"10","key":"7966_CR119","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","volume":"145","author":"P Lu","year":"2025","unstructured":"Lu P, Zhang X, Yang J, et al. Nanobody-based naturally selected CD7-targeted CAR- T therapy for acute myeloid leukemia. Blood. 2025;145(10):1022\u201333.","journal-title":"Blood"},{"key":"7966_CR120","doi-asserted-by":"publisher","first-page":"1255820","DOI":"10.3389\/fimmu.2023.1255820","volume":"14","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zeng A, Song L. Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer. Front Immunol. 2023;14:1255820.","journal-title":"Front Immunol"},{"key":"7966_CR121","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jconrel.2020.10.005","volume":"329","author":"W Gu","year":"2021","unstructured":"Gu W, Liu T, Fan D, et al. A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44\u2009+\u2009acute myeloid leukemia. J Control Release. 2021;329:706\u201316.","journal-title":"J Control Release"},{"issue":"1","key":"7966_CR122","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13045-021-01206-y","volume":"14","author":"S Xu","year":"2021","unstructured":"Xu S, Zhang M, Fang X, et al. A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia. J Hematol Oncol. 2021;14(1):193.","journal-title":"J Hematol Oncol"},{"issue":"15","key":"7966_CR123","doi-asserted-by":"publisher","first-page":"14661","DOI":"10.1021\/acsnano.4c08515","volume":"19","author":"X Xin","year":"2025","unstructured":"Xin X, Di Wu, Zhao P, et al. Catch-to-amplify nanoparticles with bacteria surface for sequential mucosal immune activation for acute myeloid leukemia therapy. ACS Nano. 2025;19(15):14661\u201379.","journal-title":"ACS Nano"},{"key":"7966_CR124","doi-asserted-by":"publisher","first-page":"124103","DOI":"10.1016\/j.ijbiomac.2023.124103","volume":"238","author":"S Fathi-Karkan","year":"2023","unstructured":"Fathi-Karkan S, Mirinejad S, Ulucan-Karnak F, et al. Biomedical applications of aptamer-modified chitosan nanomaterials: an updated review. Int J Biol Macromol. 2023;238:124103.","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"7966_CR125","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1002\/anie.202003563","volume":"60","author":"L Li","year":"2021","unstructured":"Li L, Xu S, Yan H, et al. Nucleic acid aptamers for molecular diagnostics and therapeutics: advances and perspectives. Angew Chem Int Ed Engl. 2021;60(5):2221\u201331.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"7966_CR126","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s10238-025-01724-w","volume":"25","author":"A Bayani","year":"2025","unstructured":"Bayani A, Abosaoda MK, Rizaev J, Nazari M, Jafari Z, Samarkhazan HS. Aptamer-based approaches in leukemia: a paradigm shift in targeted therapy. Clin Exp Med. 2025;25(1):186.","journal-title":"Clin Exp Med"},{"issue":"13","key":"7966_CR127","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2174\/0929867325666181008142831","volume":"27","author":"F He","year":"2020","unstructured":"He F, Wen N, Xiao D, et al. Aptamer-based targeted drug delivery systems: current potential and challenges. Curr Med Chem. 2020;27(13):2189\u2013219.","journal-title":"Curr Med Chem"},{"issue":"1","key":"7966_CR128","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12010-023-04506-w","volume":"196","author":"SS Mousavi","year":"2024","unstructured":"Mousavi SS, Ayatollahi H, Abnous K, et al. A simple aptamer-based nanoconjugate assay for diagnosis of chronic myeloid leukemia. Appl Biochem Biotechnol. 2024;196(1):145\u201359.","journal-title":"Appl Biochem Biotechnol"},{"key":"7966_CR129","doi-asserted-by":"publisher","first-page":"123495","DOI":"10.1016\/j.ijpharm.2023.123495","volume":"646","author":"SR Heydari","year":"2023","unstructured":"Heydari SR, Ghahremani MH, Atyabi F, Bafkary R, Jaafari MR, Dinarvand R. Aptamer-modified chitosan-capped mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in leukemia. Int J Pharm. 2023;646:123495.","journal-title":"Int J Pharm"},{"issue":"33","key":"7966_CR130","doi-asserted-by":"publisher","first-page":"12099","DOI":"10.1039\/D2NR02603A","volume":"14","author":"E Donadoni","year":"2022","unstructured":"Donadoni E, Siani P, Frigerio G, Di Valentin C. Multi-scale modeling of folic acid-functionalized tio(2) nanoparticles for active targeting of tumor cells. Nanoscale. 2022;14(33):12099\u2013116.","journal-title":"Nanoscale"},{"issue":"4","key":"7966_CR131","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1039\/C7SC04004K","volume":"9","author":"M Fernandez","year":"2018","unstructured":"Fernandez M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment\/imaging of cancers. Chem Sci. 2018;9(4):790\u2013810.","journal-title":"Chem Sci"},{"issue":"10","key":"7966_CR132","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.3390\/pharmaceutics15102385","volume":"15","author":"U Chitgupi","year":"2023","unstructured":"Chitgupi U, Qin Y, Ghosh S, et al. Folate-targeted nanoliposomal chemophototherapy. Pharmaceutics. 2023;15(10):2385.","journal-title":"Pharmaceutics"},{"issue":"3","key":"7966_CR133","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/pharmaceutics13030326","volume":"13","author":"M Jurczyk","year":"2021","unstructured":"Jurczyk M, Jelonek K, Musial-Kulik M, Beberok A, Wrzesniok D, Kasperczyk J. Single- versus dual-targeted nanoparticles with folic acid and biotin for anticancer drug delivery. Pharmaceutics. 2021;13(3):326.","journal-title":"Pharmaceutics"},{"key":"7966_CR134","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jconrel.2021.08.035","volume":"338","author":"S Wang","year":"2021","unstructured":"Wang S, Liu X, Wang S, et al. Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of Chronic Myeloid Leukemia. J Control Release. 2021;338:190\u2013200.","journal-title":"J Control Release"},{"key":"7966_CR135","doi-asserted-by":"publisher","first-page":"119576","DOI":"10.1016\/j.ijpharm.2020.119576","volume":"586","author":"Z Li","year":"2020","unstructured":"Li Z, Zhang Y, Zhu C, et al. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia. Int J Pharm. 2020;586:119576.","journal-title":"Int J Pharm"},{"issue":"9","key":"7966_CR136","doi-asserted-by":"publisher","first-page":"7280","DOI":"10.1021\/acsabm.1c00811","volume":"4","author":"L Li","year":"2021","unstructured":"Li L, Zhang Q, Li J, et al. Targeted delivery of doxorubicin using transferrin-conjugated carbon dots for cancer therapy. Acs Appl Bio Mater. 2021;4(9):7280\u20139.","journal-title":"Acs Appl Bio Mater"},{"issue":"17","key":"7966_CR137","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1021\/acs.accounts.1c00267","volume":"54","author":"N Song","year":"2021","unstructured":"Song N, Zhang J, Zhai J, Hong J, Yuan C, Liang M. Ferritin: a multifunctional nanoplatform for biological detection, imaging diagnosis, and drug delivery. Acc Chem Res. 2021;54(17):3313\u201325.","journal-title":"Acc Chem Res"},{"issue":"12","key":"7966_CR138","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.3390\/pharmaceutics14122574","volume":"14","author":"T Kaur","year":"2022","unstructured":"Kaur T, Upadhyay J, Pukale S, Mathur A, Ansari MN. Investigation of trends in the research on transferrin receptor-mediated drug delivery via a bibliometric and thematic analysis. Pharmaceutics. 2022;14(12):2574.","journal-title":"Pharmaceutics"},{"issue":"24","key":"7966_CR139","doi-asserted-by":"publisher","first-page":"9390","DOI":"10.3390\/ijms21249390","volume":"21","author":"M Jedrzejczyk","year":"2020","unstructured":"Jedrzejczyk M, Wisniewska K, Kania KD, Marczak A, Szwed M. Transferrin-bound doxorubicin enhances apoptosis and dna damage through the generation of pro-inflammatory responses in human leukemia cells. Int J Mol Sci. 2020;21(24):9390.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7966_CR140","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12951-023-01881-8","volume":"21","author":"X Wu","year":"2023","unstructured":"Wu X, Jiao Z, Zhang J, Li F, Li Y. Expression of tfrc helps to improve the antineoplastic effect of Ara-c on AML cells through a targeted delivery carrier. J Nanobiotechnol. 2023;21(1):126.","journal-title":"J Nanobiotechnol"},{"key":"7966_CR141","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcancer.2021.06.017","volume":"76","author":"S Medici","year":"2021","unstructured":"Medici S, Peana M, Coradduzza D, Zoroddu MA. Gold nanoparticles and cancer: detection, diagnosis and therapy. Semin Cancer Biol. 2021;76:27\u201337.","journal-title":"Semin Cancer Biol"},{"key":"7966_CR142","doi-asserted-by":"publisher","first-page":"101989","DOI":"10.1016\/j.cis.2019.101989","volume":"271","author":"V Ramalingam","year":"2019","unstructured":"Ramalingam V. Multifunctionality of gold nanoparticles: plausible and convincing properties. Adv Colloid Interface Sci. 2019;271:101989.","journal-title":"Adv Colloid Interface Sci"},{"issue":"17","key":"7966_CR143","doi-asserted-by":"publisher","first-page":"14454","DOI":"10.1021\/acsami.8b01696","volume":"10","author":"N Shen","year":"2018","unstructured":"Shen N, Yan F, Pang J, et al. Hdl-aunps-bms nanoparticle conjugates as molecularly targeted therapy for leukemia. Acs Appl Mater Interfaces. 2018;10(17):14454\u201362.","journal-title":"Acs Appl Mater Interfaces"},{"issue":"Pt 1","key":"7966_CR144","doi-asserted-by":"publisher","first-page":"128656","DOI":"10.1016\/j.ijbiomac.2023.128656","volume":"257","author":"X Enyu","year":"2024","unstructured":"Enyu X, Xinbo L, Xuelian C, Huimin C, Yin C, Yan C. Construction and performance evaluation of ph-responsive oxidized hyaluronic acid hollow mesoporous silica nanoparticles. Int J Biol Macromol. 2024;257(Pt 1):128656.","journal-title":"Int J Biol Macromol"},{"key":"7966_CR145","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2147\/DDDT.S202818","volume":"13","author":"Y Shao","year":"2019","unstructured":"Shao Y, Luo W, Guo Q, Li X, Zhang Q, Li J. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy. Drug Des Devel Ther. 2019;13:2043\u201355.","journal-title":"Drug Des Devel Ther"},{"issue":"13","key":"7966_CR146","doi-asserted-by":"publisher","first-page":"eado3923","DOI":"10.1126\/sciadv.ado3923","volume":"11","author":"S Xu","year":"2025","unstructured":"Xu S, Wang T, Hu X, et al. A dual chemodrug-loaded hyaluronan nanogel for differentiation induction therapy of refractory aml via disrupting lysosomal homeostasis. Sci Adv. 2025;11(13):eado3923.","journal-title":"Sci Adv"},{"key":"7966_CR147","doi-asserted-by":"crossref","unstructured":"Akram SM, Al-Saffar AZ, Hadi NA, Akram SM. Utilization of novel lectin-conjugated au nanoparticles as thomsen-friedenreich onco-antigen target for in vitro cytotoxicity and apoptosis induction in leukemic cell line. Life Sci. 2022;311(Pt A):121163.","DOI":"10.1016\/j.lfs.2022.121163"},{"key":"7966_CR148","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jconrel.2022.06.044","volume":"349","author":"YD Taghipour","year":"2022","unstructured":"Taghipour YD, Zarebkohan A, Salehi R, et al. An update on dual targeting strategy for cancer treatment. J Control Release. 2022;349:67\u201396.","journal-title":"J Control Release"},{"issue":"8","key":"7966_CR149","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.drudis.2022.04.011","volume":"27","author":"N Khan","year":"2022","unstructured":"Khan N, Ruchika, Dhritlahre RK, Saneja A. Recent advances in dual-ligand targeted nanocarriers for cancer therapy. Drug Discov Today. 2022;27(8):2288\u201399.","journal-title":"Drug Discov Today"},{"key":"7966_CR150","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jconrel.2023.05.032","volume":"359","author":"A Beishenaliev","year":"2023","unstructured":"Beishenaliev A, Loke YL, Goh SJ, et al. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: a review. J Control Release. 2023;359:268\u201386.","journal-title":"J Control Release"},{"issue":"3","key":"7966_CR151","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/biom10030360","volume":"10","author":"H Shim","year":"2020","unstructured":"Shim H. Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations. Biomolecules. 2020;10(3):360.","journal-title":"Biomolecules"},{"issue":"9","key":"7966_CR152","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/bloodadvances.2023011858","volume":"8","author":"Z Zeng","year":"2024","unstructured":"Zeng Z, Roobrouck A, Deschamps G, et al. Dual-targeting CD33\/CD123 nanobody(r) t cell engager with potent anti-aml activity and good safety profile. Blood Adv. 2024;8(9):2059\u201373.","journal-title":"Blood Adv"},{"issue":"1","key":"7966_CR153","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12951-020-00752-w","volume":"19","author":"KW Ho","year":"2021","unstructured":"Ho KW, Chen IU, Cheng YA, et al. Double attack strategy for leukemia using a pre-targeting bispecific antibody (cd20 ab-mpeg scfv) and actively attracting pegylated liposomal doxorubicin to enhance anti-tumor activity. J Nanobiotechnol. 2021;19(1):16.","journal-title":"J Nanobiotechnol"},{"issue":"696","key":"7966_CR154","doi-asserted-by":"publisher","first-page":"eabm1262","DOI":"10.1126\/scitranslmed.abm1262","volume":"15","author":"E Moles","year":"2023","unstructured":"Moles E, Howard CB, Huda P, et al. Delivery of pegylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia. Sci Transl Med. 2023;15(696):eabm1262.","journal-title":"Sci Transl Med"},{"issue":"8","key":"7966_CR155","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1158\/2767-9764.CRC-24-0096","volume":"4","author":"A Ali","year":"2024","unstructured":"Ali A, Phan A, Vaikari V, et al. Flt3\/CD99 bispecific antibody-based nanoparticles for Acute Myeloid Leukemia. Cancer Res Commun. 2024;4(8):1946\u201362.","journal-title":"Cancer Res Commun"},{"key":"7966_CR156","doi-asserted-by":"publisher","first-page":"126891","DOI":"10.1016\/j.cej.2020.126891","volume":"405","author":"H Bai","year":"2021","unstructured":"Bai H, Wang T, Kong F, et al. CXCR4 and CD44 dual-targeted prussian blue nanosystem with daunorubicin loaded for acute myeloid leukemia therapy. Chem Eng J. 2021;405:126891.","journal-title":"Chem Eng J"},{"issue":"11","key":"7966_CR157","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1016\/j.apsb.2020.07.012","volume":"10","author":"Y Song","year":"2020","unstructured":"Song Y, Guo X, Fu J, et al. Dual-targeting nanovesicles enhance specificity to dynamic tumor cells in vitro and in vivo via manipulation of alphavbeta3-ligand binding. Acta Pharm Sin B. 2020;10(11):2183\u201397.","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"7966_CR158","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1038\/s41565-024-01736-9","volume":"19","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Deng Y, Zhai Y, et al. A bispecific nanosystem activates endogenous natural killer cells in the bone marrow for haematologic malignancies therapy. Nat Nanotechnol. 2024;19(10):1558\u201368.","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"7966_CR159","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/pharmaceutics16020248","volume":"16","author":"S Yan","year":"2024","unstructured":"Yan S, Na J, Liu X, Wu P. Different targeting ligands-mediated drug delivery systems for tumor therapy. Pharmaceutics. 2024;16(2):248.","journal-title":"Pharmaceutics"},{"issue":"10","key":"7966_CR160","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.3390\/pharmaceutics14102115","volume":"14","author":"F Chueahongthong","year":"2022","unstructured":"Chueahongthong F, Tima S, Chiampanichayakul S, et al. Doxorubicin-loaded polymeric micelles conjugated with ckr- and evq-flt3 peptides for cytotoxicity in leukemic stem cells. Pharmaceutics. 2022;14(10):2115.","journal-title":"Pharmaceutics"},{"key":"7966_CR161","doi-asserted-by":"publisher","first-page":"119179","DOI":"10.1016\/j.ijpharm.2020.119179","volume":"579","author":"L Fan","year":"2020","unstructured":"Fan L, Liu C, Hu A, et al. Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches. Int J Pharm. 2020;579:119179.","journal-title":"Int J Pharm"},{"key":"7966_CR162","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jconrel.2022.02.012","volume":"343","author":"XH Ren","year":"2022","unstructured":"Ren XH, Xu C, Li LL, et al. A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy. J Control Release. 2022;343:645\u201356.","journal-title":"J Control Release"},{"issue":"4","key":"7966_CR163","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.biomaterials.2013.10.032","volume":"35","author":"NK Mehra","year":"2014","unstructured":"Mehra NK, Mishra V, Jain NK. A review of ligand tethered surface engineered carbon nanotubes. Biomaterials. 2014;35(4):1267\u201383.","journal-title":"Biomaterials"},{"issue":"11","key":"7966_CR164","doi-asserted-by":"publisher","first-page":"17689","DOI":"10.1021\/acsnano.1c05547","volume":"15","author":"Y Du","year":"2021","unstructured":"Du Y, Han M, Cao K, et al. Gold nanorods exhibit intrinsic therapeutic activity via controlling n6-methyladenosine-based epitranscriptomics in acute myeloid leukemia. ACS Nano. 2021;15(11):17689\u2013704.","journal-title":"ACS Nano"},{"issue":"26","key":"7966_CR165","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1039\/D1TB00548K","volume":"9","author":"H Bai","year":"2021","unstructured":"Bai H, Sun Q, Kong F, et al. Zwitterion-functionalized hollow mesoporous prussian blue nanoparticles for targeted and synergetic chemo-photothermal treatment of acute myeloid leukemia. J Mater Chem B. 2021;9(26):5245\u201354.","journal-title":"J Mater Chem B"},{"key":"7966_CR166","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.msec.2016.01.009","volume":"61","author":"SM Taghdisi","year":"2016","unstructured":"Taghdisi SM, Danesh NM, Lavaee P, et al. Double targeting, controlled release and reversible delivery of daunorubicin to cancer cells by polyvalent aptamers-modified gold nanoparticles. Mater Sci Eng C Mater Biol Appl. 2016;61:753\u201361.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"33","key":"7966_CR167","doi-asserted-by":"publisher","first-page":"e202109500","DOI":"10.1002\/anie.202109500","volume":"61","author":"L Ai","year":"2022","unstructured":"Ai L, Peng T, Li Y, et al. A dual-targeting circular aptamer strategy enables the recognition of different leukemia cells with enhanced binding ability. Angew Chem Int Ed Engl. 2022;61(33):e202109500.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"22","key":"7966_CR168","doi-asserted-by":"publisher","first-page":"2425394","DOI":"10.1002\/adfm.202425394","volume":"35","author":"A Dwivedy","year":"2025","unstructured":"Dwivedy A, Baskaran D, Sharma G, et al. Engineering novel dna nanoarchitectures for targeted drug delivery and aptamer mediated apoptosis in cancer therapeutics. Adv Funct Mater. 2025;35(22):2425394.","journal-title":"Adv Funct Mater"},{"key":"7966_CR169","doi-asserted-by":"publisher","first-page":"7983","DOI":"10.2147\/IJN.S462514","volume":"19","author":"D Xia","year":"2024","unstructured":"Xia D, Qian Q, Wang S, Dong X, Liu Y. Alendronate functionalized bone-targeting pomolic acid liposomes restore bone homeostasis for osteoporosis treatment. Int J Nanomed. 2024;19:7983\u201396.","journal-title":"Int J Nanomed"},{"key":"7966_CR170","doi-asserted-by":"publisher","first-page":"213924","DOI":"10.1016\/j.bioadv.2024.213924","volume":"162","author":"FS Abou-Elnour","year":"2024","unstructured":"Abou-Elnour FS, El-Habashy SE, Essawy MM, Abdallah OY. Alendronate\/lactoferrin-dual decorated lipid nanocarriers for bone-homing and active targeting of ivermectin and methyl dihydrojasmonate for leukemia. Biomater Adv. 2024;162:213924.","journal-title":"Biomater Adv"},{"key":"7966_CR171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DDDT.S387246","volume":"17","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Zhang W, Chen J. Binary nanodrug-delivery system designed for leukemia therapy: aptamer- and transferrin-codecorated daunorubicin- and luteolin-coloaded nanoparticles. Drug Des Devel Ther. 2023;17:1\u201313.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"7966_CR172","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1021\/acs.nanolett.4c04429","volume":"25","author":"W Wu","year":"2025","unstructured":"Wu W, Li Y, Liu Q, et al. Dual-targeted drug delivery to myeloid leukemia cells via complement- and transferrin-based protein corona. Nano Lett. 2025;25(1):147\u201356.","journal-title":"Nano Lett"},{"issue":"8","key":"7966_CR173","doi-asserted-by":"publisher","first-page":"94907663","DOI":"10.26599\/NR.2025.94907663","volume":"18","author":"Z He","year":"2025","unstructured":"He Z, Chen F, Liu H, et al. Dual-targeted self-delivery micelle co-loading doxorubicin and artesunate for enhanced aml treatment via mitochondrial damage induction. Nano Res. 2025;18(8):94907663.","journal-title":"Nano Res"},{"issue":"12","key":"7966_CR174","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41551-025-01425-5","volume":"9","author":"Y Fan","year":"2025","unstructured":"Fan Y, Zhu L, Qing Y, et al. Engineering multi-specific nano-antibodies for cancer immunotherapy. Nat Biomed Eng. 2025;9(12):2124\u201340.","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"7966_CR175","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12943-025-02501-9","volume":"24","author":"E Battistini","year":"2025","unstructured":"Battistini E, Lapuhs P, Jim\u00e9nez A, et al. Bispecific antibodies and nanotechnology:?a strategic alliance in cancer immunotherapy. Mol Cancer. 2025;24(1):292.","journal-title":"Mol Cancer"},{"issue":"19","key":"7966_CR176","doi-asserted-by":"publisher","first-page":"5905","DOI":"10.1039\/D5NA00323G","volume":"7","author":"NW Nabih","year":"2025","unstructured":"Nabih NW, Hassan HAFM, Preis E, et al. Antibody-functionalized lipid nanocarriers for rna-based cancer gene therapy: advances and challenges in targeted delivery. Nanoscale Adv. 2025;7(19):5905\u201331.","journal-title":"Nanoscale Adv"},{"issue":"2","key":"7966_CR177","doi-asserted-by":"publisher","first-page":"102520","DOI":"10.1016\/j.omtn.2025.102520","volume":"36","author":"B Dietmair","year":"2025","unstructured":"Dietmair B, Humphries J, Mercer TR, Thurecht KJ, Howard CB, Cheetham SW. Targeted mrna delivery with bispecific antibodies that tether lnps to cell surface markers. Mol Therapy Nucleic Acids. 2025;36(2):102520.","journal-title":"Mol Therapy Nucleic Acids"},{"key":"7966_CR178","doi-asserted-by":"publisher","first-page":"13818","DOI":"10.1038\/ncomms13818","volume":"7","author":"M Colombo","year":"2016","unstructured":"Colombo M, Fiandra L, Alessio G, et al. Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies. Nat Commun. 2016;7:13818.","journal-title":"Nat Commun"},{"key":"7966_CR179","unstructured":"Ang MJY, Metzloff AE, Thatte AS, Mitchell MJ. Lipid nanoparticles for engineering next generation CAR-T cell immunotherapy. Nanoscale Horiz. 2025:10\u20131039."},{"issue":"1","key":"7966_CR180","doi-asserted-by":"publisher","first-page":"2558403","DOI":"10.1080\/21645515.2025.2558403","volume":"21","author":"Y Huang","year":"2025","unstructured":"Huang Y, Cao R, Wang S, Chen X, Ping Y, Zhang Y. In vivo car-t cell therapy: new breakthroughs for cell-based tumor immunotherapy. Hum Vaccin Immunother. 2025;21(1):2558403.","journal-title":"Hum Vaccin Immunother"},{"key":"7966_CR181","doi-asserted-by":"publisher","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2025","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol. 2025;15:1519671.","journal-title":"Front Immunol"},{"issue":"12","key":"7966_CR182","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.7150\/ijbs.34213","volume":"15","author":"S Ma","year":"2019","unstructured":"Ma S, Li X, Wang X, et al. Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548\u201360.","journal-title":"Int J Biol Sci"},{"issue":"11","key":"7966_CR183","first-page":"e11504","volume":"12","author":"SM AlDallal","year":"2020","unstructured":"AlDallal SM. Yescarta: a new era for non-hodgkin lymphoma patients. Cureus. 2020;12(11):e11504.","journal-title":"Cureus"},{"issue":"2","key":"7966_CR184","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7150\/jca.48976","volume":"12","author":"D Han","year":"2021","unstructured":"Han D, Xu Z, Zhuang Y, Ye Z, Qian Q. Current progress in CAR-T cell therapy for hematological malignancies. J Cancer. 2021;12(2):326\u201334.","journal-title":"J Cancer"},{"issue":"1","key":"7966_CR185","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/fon-2022-0774","volume":"19","author":"F St-Pierre","year":"2023","unstructured":"St-Pierre F, Gordon LI. Lisocabtagene maraleucel in the treatment of relapsed\/refractory large b-cell lymphoma. Future Oncol. 2023;19(1):19\u201328.","journal-title":"Future Oncol"},{"key":"7966_CR186","doi-asserted-by":"publisher","first-page":"215949","DOI":"10.1016\/j.canlet.2022.215949","volume":"553","author":"J Yang","year":"2023","unstructured":"Yang J, Zhou W, Li D, Niu T, Wang W. Bcma-targeting chimeric antigen receptor t-cell therapy for multiple myeloma. Cancer Lett. 2023;553:215949.","journal-title":"Cancer Lett"},{"key":"7966_CR187","doi-asserted-by":"publisher","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","volume":"13","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw Dejenie T. Ciltacabtagene autoleucel: the second anti-bcma CAR-T cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022;13:991092.","journal-title":"Front Immunol"},{"issue":"1","key":"7966_CR188","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi AK, Nouri S, Hussen A, Bayani A, Khaksari MN, Samarkhazan HS. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin Exp Med. 2025;25(1):166.","journal-title":"Clin Exp Med"},{"issue":"1","key":"7966_CR189","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/acs.molpharmaceut.3c00735","volume":"21","author":"S Wang","year":"2024","unstructured":"Wang S, Wang H, Drabek A, Smith WS, Liang F, Huang ZR. Unleashing the potential: designing antibody-targeted lipid nanoparticles for industrial applications with cmc considerations and clinical outlook. Mol Pharm. 2024;21(1):4\u201317.","journal-title":"Mol Pharm"},{"issue":"5","key":"7966_CR190","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41565-025-01926-z","volume":"20","author":"Y Ju","year":"2025","unstructured":"Ju Y, Kent SJ. Balancing stealth and targeting to improve nanomedicine efficacy. Nat Nanotechnol. 2025;20(5):576\u20139.","journal-title":"Nat Nanotechnol"},{"issue":"6","key":"7966_CR191","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3390\/ph15060761","volume":"15","author":"S Andrade","year":"2022","unstructured":"Andrade S, Loureiro JA, Ramirez S, et al. Multi-dose intravenous administration of neutral and cationic liposomes in mice: an extensive toxicity study. Pharmaceuticals. 2022;15(6):761.","journal-title":"Pharmaceuticals"},{"issue":"42","key":"7966_CR192","doi-asserted-by":"publisher","first-page":"e2403409","DOI":"10.1002\/smll.202403409","volume":"20","author":"X Wu","year":"2024","unstructured":"Wu X, Wang F, Yang X, et al. Advances in drug delivery systems for the treatment of acute myeloid leukemia. Small. 2024;20(42):e2403409.","journal-title":"Small"},{"key":"7966_CR193","doi-asserted-by":"publisher","first-page":"126169","DOI":"10.1016\/j.ijpharm.2025.126169","volume":"684","author":"A Pareek","year":"2025","unstructured":"Pareek A, Alaseem AM, Alasiri G, Kapoor DU, Prajapati BG. Stimuli-responsive liposomes and niosomes in leukemia therapy: targeted delivery and clinical translation. Int J Pharm. 2025;684:126169.","journal-title":"Int J Pharm"},{"issue":"1","key":"7966_CR194","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","volume":"9","author":"D Rosenblum","year":"2018","unstructured":"Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun. 2018;9(1):1410.","journal-title":"Nat Commun"},{"key":"7966_CR195","doi-asserted-by":"publisher","first-page":"114083","DOI":"10.1016\/j.addr.2021.114083","volume":"181","author":"MA Younis","year":"2022","unstructured":"Younis MA, Tawfeek HM, Abdellatif AAH, Abdel-Aleem JA, Harashima H. Clinical translation of nanomedicines: challenges, opportunities, and keys. Adv Drug Deliv Rev. 2022;181:114083.","journal-title":"Adv Drug Deliv Rev"},{"key":"7966_CR196","doi-asserted-by":"publisher","first-page":"122126","DOI":"10.1016\/j.biomaterials.2023.122126","volume":"298","author":"ZH Alizadeh","year":"2023","unstructured":"Alizadeh ZH, Yeoh WJ, Arif M, et al. Natural killer cell-mimic nanoparticles can actively target and kill acute myeloid leukemia cells. Biomaterials. 2023;298:122126.","journal-title":"Biomaterials"},{"issue":"4","key":"7966_CR197","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41565-024-01847-3","volume":"20","author":"SRJ Hofstraat","year":"2025","unstructured":"Hofstraat SRJ, Anbergen T, Zwolsman R, et al. Nature-inspired platform nanotechnology for rna delivery to myeloid cells and their bone marrow progenitors. Nat Nanotechnol. 2025;20(4):532\u201342.","journal-title":"Nat Nanotechnol"},{"key":"7966_CR198","doi-asserted-by":"publisher","first-page":"123091","DOI":"10.1016\/j.biomaterials.2025.123091","volume":"317","author":"F Jin","year":"2025","unstructured":"Jin F, Wei X, Liu Y, et al. Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targeting. Biomaterials. 2025;317:123091.","journal-title":"Biomaterials"},{"issue":"9","key":"7966_CR199","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","volume":"19","author":"X Lian","year":"2024","unstructured":"Lian X, Chatterjee S, Sun Y, et al. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat Nanotechnol. 2024;19(9):1409\u201317.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"7966_CR200","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10(1):210.","journal-title":"Signal Transduct Target Ther"},{"issue":"6753","key":"7966_CR201","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"L Theresa","year":"2025","unstructured":"Theresa L, Hunter YBYZ. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137.","journal-title":"Science"},{"issue":"12","key":"7966_CR202","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1038\/s41551-025-01428-2","volume":"9","author":"C Ma","year":"2025","unstructured":"Ma C, Wang H, Liu L, et al. Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia. Nat Biomed Eng. 2025;9(12):2098\u2013114.","journal-title":"Nat Biomed Eng"},{"issue":"7","key":"7966_CR203","doi-asserted-by":"publisher","first-page":"7518","DOI":"10.1021\/acs.jmedchem.4c03225","volume":"68","author":"W Zhu","year":"2025","unstructured":"Zhu W, Zhao P, Liu T, et al. Discovery of novel sik2\/3 inhibitors for the potential treatment of mef2c+ Acute Myeloid Leukemia (AML). J Med Chem. 2025;68(7):7518\u201338.","journal-title":"J Med Chem"},{"issue":"12","key":"7966_CR204","doi-asserted-by":"publisher","first-page":"e70039","DOI":"10.1002\/nano.70039","volume":"6","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H, Khaksari MN, Mirzazadeh A, Siavashi M, Pilehvari N, Mohammadi MH. Nanosensors in leukemia management: pioneering real-time biomarker detection for precision oncology. Nano Select. 2025;6(12):e70039.","journal-title":"Nano Select"},{"issue":"2","key":"7966_CR205","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.nano.2016.09.014","volume":"13","author":"Y Li","year":"2017","unstructured":"Li Y, Lee RJ, Huang X, et al. Single-step microfluidic synthesis of transferrin-conjugated lipid nanoparticles for sirna delivery. Nanomedicine. 2017;13(2):371\u201381.","journal-title":"Nanomedicine"},{"issue":"6","key":"7966_CR206","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1021\/acsnano.4c16562","volume":"19","author":"W Park","year":"2025","unstructured":"Park W, Choi J, Hwang J, et al. Apolipoprotein fusion enables spontaneous functionalization of mrna lipid nanoparticles with antibody for targeted cancer therapy. ACS Nano. 2025;19(6):6412\u201325.","journal-title":"ACS Nano"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07966-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07966-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07966-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T15:04:30Z","timestamp":1775574270000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07966-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":206,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7966"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07966-w","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper does not contain any studies with human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"479"}}